Archives
-
Oligo (dT) 25 Beads: Practical mRNA Purification
2026-08-15
Oligo (dT) 25 Beads provide a magnetic workflow for enriching polyadenylated eukaryotic mRNA from total RNA, cells, or animal and plant tissues. They are appropriate for polyA-selected mRNA workflows but should not be treated as a universal method for total RNA recovery or non-polyadenylated transcript isolation.
-
JHU-083 in Glutaminase Pathway Research
2026-08-14
JHU-083 is a 6-diazo-5-oxo-L-norleucine precursor described as a selective glutaminase antagonist for experimental cerebral malaria research. Its reported activity in cerebral CD11b cells makes it a useful neurological disease model compound for studying glutamate regulation and excitotoxicity.
-
PRMT5, Splicing, and Glutamine Dependence in Neuroblastoma
2026-08-14
The reference study shows that MYCN-amplified neuroblastoma is unusually vulnerable to PRMT5 inhibition because PRMT5 controls interconnected splicing, epitranscriptomic, and glutamine-metabolic programs. Its combination of transcriptomics, stable-isotope tracing, molecular validation, and mouse studies provides a mechanistic framework for cancer metabolism research and hypothesis-driven preclinical cancer drug evaluation.
-
Palonosetron for CINV: Evidence and Research Implications
2026-08-13
The reference review explains why palonosetron hydrochloride differs pharmacologically from earlier 5-HT3 receptor antagonists, emphasizing prolonged receptor engagement, allosteric binding, and positive cooperativity. Its clinical interpretation suggests a durable role in acute and delayed chemotherapy-induced nausea and vomiting prevention, while also highlighting the limits of cross-trial comparisons and nausea-focused endpoints.
-
AMPK–SQSTM1 Feedback Loop Under Metabolic Stress
2026-08-13
Cho et al. identify a double-positive feedback loop in which metabolic stress activates both AMPK and SQSTM1/p62, while AMPK activity reinforces p62 expression and phosphorylation. The mechanism connects lysosomal remodeling, TAK1-dependent p62 phosphorylation, KEAP1 degradation, and NRF2 activation, providing a framework for understanding antioxidant adaptation in STK11- and KEAP1-altered lung cancer.
-
E-64: From Cysteine Protease Tool to Immune Insight
2026-08-12
E-64 is an irreversible L-trans-epoxysuccinyl peptide that enables rigorous cysteine protease inhibition studies. This thought-leadership analysis connects its biochemical utility with cathepsin S biology, lymphoma antigen processing, experimental design, and translational decision-making.
-
Bradykinin BA5201: Vascular Assay Guide
2026-08-12
This guide explains how to handle Bradykinin (BA5201) as a controlled research stimulus for endothelial, vascular permeability, smooth muscle, pain, and inflammation assays. It is intended for scientific research only; solutions should be used promptly, and the product should not be used for diagnostic, therapeutic, or medical applications.
-
JHU-083 for Glutaminase Pathway Research
2026-08-11
JHU-083 is a 6-diazo-5-oxo-L-norleucine precursor designed for selective glutaminase pathway studies in cerebral CD11b cells and experimental cerebral malaria research. This workflow-focused guide shows how to connect glutamate measurements with redox, cell-identity, and disease-model readouts without confusing hepatic oxidative-stress evidence with direct neurological validation.
-
JHU-083: From Glutaminase Biology to Translation
2026-08-11
JHU-083 connects cell-selective glutaminase inhibition with glutamate biology in experimental cerebral malaria. This thought-leadership article outlines mechanistic rationale, validation workflows, redox hypotheses inspired by GSTA1 research, translational limitations, and strategic opportunities for neurological disease model development.
-
Hyperglycemia, Pin1/BRD4, and Gastric Cancer
2026-08-10
The reference study identifies a Pin1/BRD4 signaling axis through which high glucose promotes gastric carcinoma proliferation, cell-cycle progression, and migration. By combining cellular perturbation with tumor-growth and lung-metastasis models, it connects diabetic hyperglycemia to a testable cancer mechanism and highlights pathway inhibition as a potential experimental strategy.
-
IDH2, Ferroptosis, and TNBC Proliferation
2026-08-09
This study identifies wild-type IDH2 as a ferroptosis-associated regulator that supports triple-negative breast cancer proliferation. By integrating tumor datasets with clinical, cellular, and mouse-model validation, it connects redox metabolism to a potentially actionable vulnerability in TNBC and clarifies how DNA synthesis measurements can complement mechanistic studies.
-
Rice Stripe Virus NS3 Rewires Host Signaling
2026-08-08
Zhuang et al. show that Rice stripe virus NS3 switches between distinct functions during infection: early self-interaction suppresses antiviral RNA interference, whereas later phosphorylation and interaction with OsSnRK3.25 reshape ROS, programmed cell death, pathogenicity, and transmission. The study provides a mechanistic model of virus–plant–vector co-survival and highlights why infection stage and host context are essential experimental variables.
-
Sumatriptan Succinate in Translational Research
2026-08-07
Learn how to use Sumatriptan as a 5-HT1 receptor agonist across receptor, inflammation, metabolism, and neurovascular workflows. A pediatric emergency department study provides a clinically relevant framework for choosing route-aware assays, pain-related endpoints, and practical translational controls.
-
PYR-41, Inhibitor of Ubiquitin-Activating Enzyme E1: Advance
2026-08-07
PYR-41 empowers researchers to dissect the ubiquitin-proteasome system with precision, unlocking new opportunities for antiviral, inflammation, and apoptosis studies. This article translates complex bench research and recent virology insights into practical workflows, protocol optimization, and troubleshooting strategies for robust, reproducible results.
-
Protease Inhibitor Cocktail: Precision Protein Extraction En
2026-08-06
Unlock uncompromised protein integrity in phosphorylation-sensitive workflows with APExBIO’s Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO). This advanced, EDTA-free formulation delivers robust protein degradation prevention for Western blot, Co-IP, and kinase assays—optimizing sensitive experiments where conventional inhibitors fall short.